

RD General Agenda Topics – October 20, 2020

New Active Ingredients (include original PRIA date)

- Inpyrfluxam – Complete
- Pethoxamid – complete
- Pyridate – complete
- Tiafenacil – complete
- Tetraniliprole – PD signed, PRIA date 12/24/20 (Original PRIA date 3/27/19) (IVB3)

Ex. 5 Deliberative Process (DP)

Chemical Actions

- Dicamba (Dan K)
 - **Docs due to Alex Wednesday and Thursday**
 - Antibiotics – developing comparison schedule (Cynthia)
 - Streptomycin – developing RTC
 - Oxytet – cherry; Dec; public process
 - Consultation with partners – Kasugamycin (almond, peach, apricot)
 - **OD briefing in November**
 - Aldicarb – registrant agreed to 60 days; water refinement; RD is regrouping with EFED/HED; Another renegotiation likely (Marion)
 - **Spirodiclofen – Gowan purchasing reg review vs. new AI (Meredith)**
 - Cyclaniliprole/flonicamid – RD IO review; first residential use; public process; bee language; coming to OPP IO soon
 - **Seresto – pet collar with high rate of incidents (death and neuro); does OPP-IO want a briefing?**
- Other Actions - AA-Level/OD/High Visibility Items
- COVID-19 Activities – Sect 18s –
 - **SW2 – OK has submitted**

Ex. 5 Deliberative Process (DP)

- Formulator's exemption (Bo)
 - **Drafting new memo (awaiting comments from OGC)**
 - Syngenta – request to cancel Atticus registrations
 - OGC is proposing that we write up something short that explains that, during the time of approval, RD was following all of our current policies.

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

ont: 11 pt

Speaking Engagements –

- Gold Seal Updates for CLA/RISE Workgroup (Catherine Aubee, Shanta Adeeb, Marion Johnsons, ITRMD participant), mid-Nov (date TBD)

Ex. 5 Deliberative Process (DP)